Thursday, 11 December 2014
Ceritinib in ALK-rearranged non-small-cell lung cancer
Ceritinib is a new oral highly potent and selective ALK inhibitor. Shaw et al, conducted a phase 1 study of Ceritinib to determine safety, maximum tolerated dose (MTD), pharmacokinetic properties and anti-tumour effects in patients with ALK-rearranged tumours. Read more here.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment